Literature DB >> 18425913

Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.

V Dalbello-Haas1, J M Florence, L S Krivickas.   

Abstract

BACKGROUND: Despite the high incidence of muscle weakness in individuals with amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND), the effects of exercise in this population are not well understood.
OBJECTIVES: The objective was to systematically review randomised and quasi-randomised studies of exercise for people with ALS or MND. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group Trials Register, EMBASE (January 1980 to August 2007), LILACS (January 1982 to August 2007), MEDLINE (January 1966 to August 2007), Cochrane Central Register of Controlled Trials (CENTRAL), PEDro (January 1980 to August 2007), AMED (January 1985 to August 2007), HealthSTAR (January 1975 to August 2007), CINAHL (January 1982 to August 2007). We also searched Dissertation Abstracts, inspected the reference lists of all papers selected for review and contacted the authors with expertise in the field. SELECTION CRITERIA: We included randomised or quasi-randomised controlled trials of people with a diagnosis of definite, probable, probable with laboratory support, or possible amyotrophic lateral sclerosis, as defined by the El Escorial criteria. We included progressive resistance or strengthening exercise and endurance or aerobic exercise. The control condition was no exercise or standard rehabilitation management. Our primary outcome measure was improvement in functional ability, decrease in disability or reduction in rate of decline as measured by a validated outcome tool at three months. Our secondary outcome measures were improvement in psychological status or quality of life, decrease in fatigue, increase in, or reduction in rate of decline of muscle strength (strengthening or resistance studies), increase in, or reduction in rate of decline of aerobic endurance (aerobic or endurance studies) at three months and frequency of adverse effects. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted the data. The authors of the papers were contacted to obtain information not available in the published articles. MAIN
RESULTS: We identified two randomised controlled trials that met our inclusion criteria. The first examined the effects of a twice-daily exercise program of moderate load, endurance exercise versus "usual activities" in 25 people with ALS. The second examined the effects of thrice weekly moderate load and moderate intensity resistance exercises compared to usual care (stretching exercises) in 27 people with ALS. After three months, when the results of the two trials were combined, there was a significant weighted mean improvement in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) measure of function in the exercise compared with the control groups (3.21, 95% confidence interval 0.46 to 5.96) in favour of the exercise group. No statistically significant differences in quality of life, fatigue or muscle strength were found. AUTHORS'
CONCLUSIONS: The only studies detected were too small to determine to what extent strengthening exercises for people with ALS are beneficial, or whether exercise is harmful. There is a complete lack of randomised or quasi-randomised clinical trials examining aerobic exercise in this population. More research is needed.

Entities:  

Mesh:

Year:  2008        PMID: 18425913     DOI: 10.1002/14651858.CD005229.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  21 in total

Review 1.  Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

Authors:  Rachna S Pandya; Lilly L J Mao; Edward W Zhou; Robert Bowser; Zhenglun Zhu; Yongjin Zhu; Xin Wang
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

2.  Amyotrophic lateral sclerosis and the neuroprotective potential of exercise.

Authors:  Matthew C Kiernan
Journal:  J Physiol       Date:  2009-08-01       Impact factor: 5.182

Review 3.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

4.  Biomechanical strain vehicles for fibroblast-directed skeletal myoblast differentiation and myotube functionality in a novel coculture.

Authors:  Michael R Hicks; Thanh V Cao; Paul R Standley
Journal:  Am J Physiol Cell Physiol       Date:  2014-10-15       Impact factor: 4.249

5.  Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Satya L Reddy; Diane E Merry; Hiroaki Adachi; Masahisa Katsuno; Gen Sobue; Diane M Robins; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2013-10-22       Impact factor: 6.150

Review 6.  The neuropathological signature of bulbar-onset ALS: A systematic review.

Authors:  S Shellikeri; V Karthikeyan; R Martino; S E Black; L Zinman; J Keith; Y Yunusova
Journal:  Neurosci Biobehav Rev       Date:  2017-02-02       Impact factor: 8.989

Review 7.  Exercise and amyotrophic lateral sclerosis.

Authors:  J P Lopes de Almeida; R Silvestre; A C Pinto; M de Carvalho
Journal:  Neurol Sci       Date:  2012-01-07       Impact factor: 3.307

Review 8.  WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.

Authors:  Cathy Payne; Philip J Wiffen; Suzanne Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-04-07

Review 9.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 10.  Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.

Authors:  Vanina Dal Bello-Haas; Julaine M Florence
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.